REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
American Journal of Psychiatry December 22, 2021 Maurizio Fava, S. Stahl, Luca Pani et al.
OBJECTIVE The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. METHODS A 7-day phase 2 multicenter randomized double-blind placebo-controlled...